The company has set aside 35% of the net offer for individual investors, 50% for qualified institutional buyers and 15% for non-institutional buyers.
Image Credit source: File Photo
Mankind Pharma Limited will present its first IPO to the general public on Tuesday with the aim of raising Rs 4,326 crore. The domestically interested pharma maker will make an offer for sale of approximately 4 crore shares. Delhi-based Mankind Pharma is eyeing a market value of Rs 43,264 crore at the upper end of the price band of Rs 1,026-1,080. The company has set aside 35% of the net offer for individual investors, 50% for qualified institutional buyers and 15% for non-institutional buyers.
Mankind Pharma’s IPO is priced at 10% of the issue size, and ChrysCapital and Capital International are divesting 2.5% of their holdings respectively. After the offer, the promoter’s shareholding will be 76.5%. Let us tell you that with the opening of the IPO of Mankind Pharma, common people can earn well.
Mankind is the third largest pharmaceutical company
Mankind Pharma works in the areas of Indian Pharmaceutical Formulation and Consumer Healthcare. According to IQVIA MAT December 2022, Mankind Pharma is India’s fourth largest pharmaceutical company in terms of domestic sales and third largest in terms of sales volume. The company has one of the largest distribution network of medical representatives.
read this also – 55 companies are in the race for the future Will compete with Adani-Ambani
The company is engaged in the development, manufacturing and marketing of a wide variety of pharmaceutical formulations in various acute and chronic therapeutic areas, which include anti-infective, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamin/mineral/nutrient and respiratory Are. The company is focusing on the domestic market. India accounted for 97.6% of their total revenue from operations in FY22. This was the highest among peers identified by IQVIA.
36 brands in the pharmaceutical business
Explain that their international sales come from products sold in 21 countries such as the United States, Latin America, Southeast Asia, Africa, the Middle East and the Commonwealth of Independent States. The company has mainly grown organically. It has built 36 brands in its pharmaceutical business, each of which has achieved a milestone of over Rs 50 crore in domestic sales for MAT December 2022. Between FY20 and MAT December 2022, the company’s domestic sales grew at a CAGR of approximately 12%, while the Indian pharma market grew at a CAGR of approximately 10% during the same period.
read this also – Another bank may meet the same fate as Silicon Valley and Signature Bank, know the whole matter
customer health service
The company’s consumer health care products range from condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements to anti-acne preparations. As per MAT December 2022, Mankind Pharma’s brands were the leaders in this category. Male condom category, where Manforce brand sales represent a market share of around 29.6%. In the pregnancy detection kit category, the market share of Prega News brand sales was around 79.7%. The emergency contraceptive category, where domestic sales of the Unwanted-72 brand represent a market share of around 61.7%.